<DOC>
	<DOCNO>NCT00163527</DOCNO>
	<brief_summary>Bronchial asthma among world 's prevalent disease . Roflumilast novel , orally active , selective enzyme inhibitor ( phosphodiesterase 4 inhibitor ) , show effectiveness treatment asthma . The aim study investigate effect roflumilast take orally together low dose inhale corticosteroid lung function . Roflumilast administer one dose level daily together inhaled corticosteroid one dose level twice daily . The study duration consist baseline period ( 2 6 week ) treatment period ( 24 week ) . The study provide data safety , tolerability , effectiveness roflumilast .</brief_summary>
	<brief_title>Efficacy Safety Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids Patients With Asthma ( 12 70 ) ( BY217/M2-013 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Main Written inform consent Diagnosis persistent chronic bronchial asthma , accord Global Initiative Asthma ( GINA ) guideline The patient receive BDP CFC â‰¤1000 mcg per day equivalent previous four week FEV1 60 90 % predict visit 1 No change asthma treatment within 4 week prior visit 1 Main Patients poorly control asthma define require course oral parenteral corticosteroid , admission hospital asthma ( include treatment emergency room ) , exacerbation asthma four week prior visit 1 Patients suffer seasonal asthma alone patient likely major exacerbation asthma due seasonal effect study runin treatment period A history lower airway infection four week prior visit 1 A diagnosis chronic obstructive pulmonary disease ( COPD ) and/or relevant lung disease ( e.g . cystic fibrosis , bronchiectasis ) Heavy smoker currently smoke &gt; 20 cigarette per day and/or &gt; 10 pack year patient exsmoker smoke &gt; 10 pack year Patients use &gt; 8 puffs/day relief medication regularly prior visit 1 Clinically relevant abnormal laboratory value suggest unknown disease require clinical evaluation A diagnosis , treatment remission cancer ( basal cell carcinoma ) within two year prior visit 1 Patients chronic heart failure class III IV ( New York Heart Association ) Suspected hypersensitivity and/or contraindication ingredient study medication ( roflumilast , BDP , salbutamol ) A history alcoholism substance abuse within 12 month prior visit 1 Pregnancy woman childbearing potential use reliable method contraception</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Roflumilast</keyword>
	<keyword>Corticosteroids</keyword>
</DOC>